See more : Tianjin Hi-Tech Development Co.,Ltd. (600082.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Vericel Corporation (VCEL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vericel Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Celtic plc (CCP.L) Income Statement Analysis – Financial Results
- ASN Broker Public Company Limited (ASN.BK) Income Statement Analysis – Financial Results
- Mitsubishi Corporation (MTSUY) Income Statement Analysis – Financial Results
- Patriot Battery Metals Inc. (PMETF) Income Statement Analysis – Financial Results
- IKIO Lighting Limited (IKIO.NS) Income Statement Analysis – Financial Results
Vericel Corporation (VCEL)
About Vericel Corporation
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 197.52M | 164.37M | 156.18M | 124.18M | 117.85M | 90.86M | 63.92M | 54.38M | 51.17M | 28.80M | 19.00K | 21.00K | 18.00K | 89.00K | 182.00K | 522.00K | 685.00K | 863.00K | 909.00K | 1.30M | 844.00K | 877.00K | 899.00K | 1.15M | 881.00K | 249.00K | 400.00K | 1.60M |
| Cost of Revenue | 61.94M | 54.58M | 50.16M | 39.95M | 37.57M | 32.16M | 30.35M | 28.31M | 26.47M | 17.29M | 4.00K | 6.00K | 4.00K | 34.00K | 112.00K | 56.00K | 29.00K | 11.00K | 148.00K | 280.00K | 893.00K | 202.00K | 13.00K | 926.00K | 6.00K | 0.00 | -500.00K | 9.60M |
| Gross Profit | 135.58M | 109.79M | 106.03M | 84.23M | 80.28M | 58.70M | 33.57M | 26.08M | 24.70M | 11.50M | 15.00K | 15.00K | 14.00K | 55.00K | 70.00K | 466.00K | 656.00K | 852.00K | 761.00K | 1.02M | -49.00K | 675.00K | 886.00K | 224.00K | 875.00K | 249.00K | 900.00K | -8.00M |
| Gross Profit Ratio | 68.64% | 66.80% | 67.88% | 67.83% | 68.12% | 64.60% | 52.52% | 47.95% | 48.27% | 39.95% | 78.95% | 71.43% | 77.78% | 61.80% | 38.46% | 89.27% | 95.77% | 98.73% | 83.72% | 78.49% | -5.81% | 76.97% | 98.55% | 19.48% | 99.32% | 100.00% | 225.00% | -500.00% |
| Research & Development | 21.04M | 19.94M | 16.29M | 13.02M | 30.39M | 13.60M | 12.94M | 15.30M | 18.89M | 21.26M | 15.10M | 26.03M | 21.33M | 12.66M | 11.29M | 15.25M | 11.44M | 9.48M | 7.21M | 6.29M | 5.65M | 5.43M | 4.98M | 6.29M | 10.87M | 15.50M | 13.40M | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 49.01M | 35.61M | 27.39M | 22.48M | 13.77M | 5.88M | 7.75M | 0.00 | 5.20M | 4.95M | 6.44M | 8.68M | 9.10M | 5.97M | 5.39M | 4.02M | 3.53M | 2.48M | 3.36M | 2.84M | 2.86M | 2.00M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 121.00M | 106.90M | 97.59M | 68.84M | 61.14M | 49.01M | 35.61M | 27.39M | 22.48M | 13.77M | 5.88M | 7.75M | 7.72M | 5.20M | 4.95M | 6.44M | 8.68M | 9.10M | 5.97M | 5.39M | 4.02M | 3.53M | 2.48M | 3.36M | 2.84M | 2.86M | 2.00M | 2.10M |
| Other Expenses | 0.00 | 95.00K | 52.00K | -13.00K | -20.00K | -31.00K | -92.00K | -10.00K | 47.00K | -2.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.21M | 5.64M | 5.64M | 0.00 | 325.00K | 0.00 | 0.00 | 500.00K | 400.00K |
| Operating Expenses | 142.04M | 126.85M | 113.88M | 81.86M | 91.53M | 62.61M | 48.55M | 42.68M | 41.37M | 35.04M | 20.98M | 33.78M | 29.05M | 17.86M | 16.24M | 21.69M | 20.13M | 18.59M | 13.18M | 11.68M | 9.66M | 8.96M | 7.47M | 9.98M | 13.71M | 18.36M | 15.90M | 2.50M |
| Cost & Expenses | 203.98M | 181.42M | 164.04M | 121.81M | 129.10M | 94.77M | 78.91M | 70.99M | 67.84M | 52.33M | 20.98M | 33.78M | 29.06M | 17.89M | 16.35M | 21.74M | 20.15M | 18.60M | 13.33M | 11.96M | 10.56M | 9.16M | 7.48M | 10.90M | 13.71M | 18.36M | 15.40M | 12.10M |
| Interest Income | 4.63M | 1.34M | 224.00K | 691.00K | 1.61M | 897.00K | 14.00K | 8.00K | 36.00K | 24.00K | 16.00K | 50.00K | 53.00K | 115.00K | 296.00K | 1.17M | 1.26M | 594.00K | 594.00K | 169.00K | 134.00K | 342.00K | 364.00K | 364.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 600.00K | 366.00K | 4.00K | 6.00K | 8.00K | 1.73M | 1.11M | 314.00K | 9.00K | 6.00K | 11.00K | 12.00K | 10.00K | 40.00K | 73.00K | 73.00K | 84.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 4.63M | 8.20M | 7.39M | 6.83M | 4.53M | 1.43M | 1.61M | 1.89M | 1.59M | 752.00K | 489.00K | 649.00K | 647.00K | 592.00K | 704.00K | 351.00K | -47.00K | 191.00K | 99.00K | 125.00K | 119.00K | 126.00K | 102.00K | 325.00K | 226.00K | 377.00K | 500.00K | 400.00K |
| EBITDA | 2.86M | -11.64M | -4.61M | 9.88M | -5.13M | -4.98M | -14.57M | -17.37M | -14.74M | -19.16M | -15.12M | -28.81M | -19.01M | -30.15M | -17.80M | -15.47M | -21.22M | -19.47M | -17.73M | -12.42M | -10.36M | -9.71M | -8.16M | -6.48M | -9.43M | -12.62M | -17.75M | -14.50M |
| EBITDA Ratio | 1.45% | -9.50% | -4.85% | 2.46% | -8.19% | -3.35% | -23.56% | -30.54% | -32.42% | -81.65% | -107,678.95% | -157,433.33% | -209,566.67% | -19,339.33% | -8,497.25% | -3,997.70% | -2,842.19% | -2,032.68% | -1,356.44% | -808.91% | -1,136.73% | -929.87% | -720.47% | -819.91% | -1,571.28% | -7,120.48% | -3,800.00% | -675.00% |
| Operating Income | -6.46M | -17.06M | -7.85M | 667.00K | -11.25M | -3.91M | -14.98M | -19.25M | -16.67M | -23.53M | -20.96M | -33.76M | -29.04M | -17.80M | -16.17M | -21.22M | -19.47M | -17.73M | -12.42M | -10.66M | -9.71M | -8.28M | -6.58M | -9.75M | -12.83M | -18.11M | -15.00M | -10.50M |
| Operating Income Ratio | -3.27% | -10.38% | -5.03% | 0.54% | -9.55% | -4.30% | -23.44% | -35.39% | -32.58% | -81.73% | -110,336.84% | -160,761.90% | -161,333.33% | -20,004.49% | -8,884.07% | -4,064.94% | -2,842.19% | -2,054.81% | -1,366.01% | -818.51% | -1,150.83% | -944.24% | -731.81% | -848.17% | -1,456.53% | -7,271.89% | -3,750.00% | -656.25% |
| Total Other Income/Expenses | 4.10M | 1.07M | 272.00K | 672.00K | 1.59M | -4.23M | -2.30M | -321.00K | 331.00K | 3.61M | 5.34M | 4.29M | 9.37M | -20.37M | 1.86M | 223.00K | 1.09M | 1.88M | 1.26M | 606.00K | 169.00K | 134.00K | -1.11M | 364.00K | 1.24M | 0.00 | 3.85M | 5.20M |
| Income Before Tax | -2.37M | -15.99M | -7.58M | 3.04M | -9.67M | -8.14M | -17.29M | -19.57M | -16.34M | -19.92M | -15.62M | -29.47M | -19.71M | -17.73M | -15.95M | -20.13M | -16.48M | -11.81M | -12.41M | -10.49M | -9.58M | -7.94M | -9.39M | -9.39M | -11.60M | 0.00 | -14.30M | -9.80M |
| Income Before Tax Ratio | -1.20% | -9.73% | -4.85% | 2.45% | -8.20% | -8.96% | -27.04% | -35.98% | -31.93% | -69.18% | -82,221.05% | -140,352.38% | -109,505.56% | -19,920.22% | -8,761.54% | -3,856.90% | -2,405.11% | -1,368.60% | -1,364.69% | -805.53% | -1,134.95% | -905.25% | -1,044.49% | -816.52% | -1,316.12% | 0.00% | -3,575.00% | -612.50% |
| Income Tax Expense | 814.00K | 721.00K | -111.00K | 180.00K | -1.76M | 3.36M | 1.12M | 2.64M | -257.00K | -3.60M | -5.34M | -4.25M | -18.71M | -115.00K | -296.00K | -1.09M | -1.83M | -1.26M | -618.00K | -169.00K | -134.00K | -342.00K | -653.00K | -364.00K | -3.04M | -874.00K | -1.40M | -1.30M |
| Net Income | -3.18M | -16.71M | -7.47M | 2.86M | -7.91M | -8.14M | -17.29M | -19.57M | -16.34M | -19.92M | -15.62M | -29.47M | -19.67M | -17.73M | -15.95M | -20.13M | -17.59M | -16.48M | -11.81M | -10.49M | -9.58M | -7.94M | -5.93M | -9.39M | -11.03M | -17.23M | -14.30M | -9.90M |
| Net Income Ratio | -1.61% | -10.17% | -4.78% | 2.31% | -6.71% | -8.96% | -27.04% | -35.98% | -31.93% | -69.18% | -82,221.05% | -140,352.38% | -109,266.67% | -19,920.22% | -8,761.54% | -3,856.90% | -2,568.47% | -1,909.04% | -1,299.34% | -805.53% | -1,134.95% | -905.25% | -659.18% | -816.52% | -1,251.76% | -6,920.88% | -3,575.00% | -618.75% |
| EPS | -0.07 | -0.35 | -0.16 | 0.06 | -0.18 | -0.20 | -0.52 | -0.85 | -0.69 | -1.71 | -5.18 | -14.31 | -10.19 | -14.34 | -17.84 | -24.95 | -23.55 | -24.79 | -20.20 | -22.77 | -30.06 | -30.16 | -27.86 | -64.36 | -115.01 | -206.34 | -203.20 | -171.20 |
| EPS Diluted | -0.07 | -0.35 | -0.16 | 0.06 | -0.18 | -0.20 | -0.52 | -0.85 | -0.69 | -1.71 | -5.18 | -14.31 | -10.19 | -14.34 | -17.84 | -24.95 | -23.55 | -24.79 | -20.20 | -22.77 | -30.06 | -30.16 | -27.86 | -64.36 | -115.01 | -206.34 | -203.20 | -171.20 |
| Weighted Avg Shares Out | 47.59M | 47.13M | 46.47M | 45.22M | 44.18M | 40.24M | 33.35M | 23.09M | 23.76M | 11.64M | 3.02M | 2.06M | 1.93M | 1.24M | 893.85K | 807.00K | 747.02K | 664.46K | 584.63K | 460.64K | 318.65K | 263.26K | 212.69K | 145.90K | 95.89K | 83.52K | 70.37K | 57.83K |
| Weighted Avg Shares Out (Dil) | 47.59M | 47.13M | 46.47M | 47.28M | 44.18M | 40.24M | 33.36M | 23.09M | 23.76M | 11.64M | 3.02M | 2.06M | 1.93M | 1.24M | 893.85K | 807.00K | 747.02K | 664.46K | 584.63K | 460.64K | 318.65K | 263.26K | 212.69K | 145.90K | 95.89K | 83.52K | 70.37K | 57.83K |
Vericel Corporation (VCEL) is on the Move, Here's Why the Trend Could be Sustainable
If you are looking for stocks that are well positioned to maintain their recent uptrend, Vericel Corporation (VCEL) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Vericel to Report Fourth-Quarter and Full-Year 2023 Financial Results on February 29, 2024
CAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its fourth-quarter and full-year 2023 financial results on Thursday,...
5 medical stocks growing earnings by triple digits
While most of the market focuses on hyper-growth technology stocks rewarded by Wall Street as long as they mention the word "artificial intelligence" in their earnings calls, the reality is that the fundamentals now favor other (safer) areas of the economy.
Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024
CAMBRIDGE, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will present at the Canaccord Genuity Musculoskeletal...
Recent Price Trend in Vericel Corporation (VCEL) is Your Friend, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Vericel Corporation (VCEL) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Vericel Corporation (VCEL) Moves 7.0% Higher: Will This Strength Last?
Vericel Corporation (VCEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Vericel Announces Preliminary Full-Year and Fourth Quarter 2023 Financial Results
Full-Year Total Revenue Expected to be Approximately $197.5 Million, Representing 20% Growth, with Fourth Quarter Revenue Growth of 23% to $65 Million
Vericel to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will present at the 42nd Annual J.P....
3 Biotech Stocks That Could Boom or Bust by 2025
InvestorPlace published an article last December about the seven hottest biotech stocks to own in 2023 and beyond. One of the seven was the SPDR S&P Biotech ETF (NYSEARCA: XBI ).
3 Strong Buy Stocks Set to Take Off in the Coming Months
Some of the most followed information in the stock market besides earnings releases are analyst recommendations. These are expert analyses that cover various companies that have a high potential for return on investment or industries in which they specialize.
Source: https://incomestatements.info
Category: Stock Reports